{"id":412110,"date":"2021-01-11T09:03:45","date_gmt":"2021-01-11T14:03:45","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412110"},"modified":"2021-01-11T09:03:45","modified_gmt":"2021-01-11T14:03:45","slug":"robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/","title":{"rendered":"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the <i>Minerva Neurosciences, Inc.<\/i> Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRobbins Geller Rudman &amp; Dowd LLP announces that purchasers of Minerva Neurosciences, Inc. (NASDAQ:NERV) common stock between May 15, 2017 and November 30, 2020, inclusive (the \u201cClass Period\u201d), have until February 8, 2021 to seek appointment as lead plaintiff in the <i>Minerva<\/i> class action lawsuit, <i>McCoy v. Minerva Neurosciences, Inc.<\/i>,<i \/>No. 20-cv-12176 (D. Mass.), which is assigned to Judge George A. O\u2019Toole, Jr. The <i>Minerva <\/i>class action lawsuit charges Minerva and its Chief Executive Officer with violations of the Securities Exchange Act of 1934.\n<\/p>\n<p>\nThe Private Securities Litigation Reform Act of 1995 permits any investor who purchased Minerva common stock during the Class Period to seek appointment as lead plaintiff in the <i>Minerva <\/i>class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the <i>Minerva <\/i>class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the <i>Minerva<\/i> class action lawsuit. An investor\u2019s ability to share in any potential future recovery of the <i>Minerva<\/i> class action lawsuit is not dependent upon serving as lead plaintiff. <b>If you wish to serve as lead plaintiff of the <i>Minerva<\/i><\/b><b>class action lawsuit or have questions concerning your rights regarding the <i>Minerva<\/i><\/b><b>class action lawsuit, please provide your information <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-minerva-neurosciences-inc-class-action-lawsuit.html&amp;esheet=52358928&amp;newsitemid=20210111005062&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=3bf4f9e830f89ca9b777366b2d1ba691\">here<\/a> or contact counsel, J.C. Sanchez of Robbins Geller, at 800\/449-4900 or 619\/231-1058 or via e-mail at <a rel=\"nofollow\" href=\"mailto:jsanchez@rgrdlaw.com\">jsanchez@rgrdlaw.com<\/a>. Lead plaintiff motions for the <i>Minerva<\/i><\/b><b>class action lawsuit must be filed with the court no later than February 8, 2021.<\/b><\/p>\n<p>\nMinerva is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Minerva\u2019s lead product candidate, roluperidone (MIN-101), is in development for the treatment of negative symptoms in patients with schizophrenia. In October 2016, Minerva reported positive results from a Phase 2b trial of roluperidone for this treatment, asserting that the \u201c[d]ata show continuous improvement in negative symptoms, stable positive symptoms and extended safety profile.\u201d Thereafter, on May 15, 2017, Minerva announced that it would proceed to a Phase 3 clinical trial for roluperidone following a successful \u201cend-of-Phase 2\u201d meeting with the U.S. Food and Drug Administration (\u201cFDA\u201d). In doing so, Minerva\u2019s Chief Executive Officer, defendant R\u00e9my Luthringer, stated that \u201c[o]ur discussion with the [FDA] has helped to confirm our Phase 3 trial design, which is similar to our previous Phase 2b trial design. We believe that positive data from the Phase 3 trial, along with the positive data from the Phase 2b trial, may form the basis for the future submission of a New Drug Application [NDA] for [roluperidone] with the FDA.\u201d\n<\/p>\n<p>\nThe <i>Minerva <\/i>class action lawsuit alleges that, throughout the Class Period, defendants made false and\/or misleading statements and\/or failed to disclose: (i) the truth about the feedback received from the FDA concerning the \u201cend-of-Phase 2\u201d meeting; (ii) that the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) that the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) that Minerva\u2019s plan to use the combination of the Phase 2b and Phase 3 studies would be \u201chighly unlikely\u201d to support the submission of an NDA; (v) that reliance on these two trials in the submission of an NDA would lead to \u201csubstantial review issues\u201d because the trials were inadequate and not well controlled; and (vi) that, as a result, Minerva\u2019s public statements were materially false and misleading at all relevant times.\n<\/p>\n<p>\nOn May 29, 2020, Minerva released the results of its Phase 3 clinical trial, revealing that the studied \u201cdoses were not statistically significantly different from placebo at Week 12 on the primary endpoint . . . or the key secondary endpoint.\u201d On this news, Minerva\u2019s stock price fell nearly 73%.\n<\/p>\n<p>\nThen, on December 1, 2020, Minerva revealed that the \u201cFDA advised that the Phase 2b study is problematic because it did not use the commercial formulation of roluperidone and was conducted solely outside of the United States. In addition, FDA commented that the Phase 3 study does not appear to be capable of supporting substantial evidence of effectiveness . . . .\u201d Indeed, the \u201cFDA cautioned that an NDA submission based on the current data from the Phase 2b and Phase 3 studies would be highly unlikely to be filed and that at a minimum, there would be substantial review issues due to the lack of two adequate and well-controlled trials to support efficacy claims for this indication.\u201d On this news, Minerva\u2019s stock price fell an additional 25%, further damaging investors.\n<\/p>\n<p>\nRobbins Geller Rudman &amp; Dowd LLP is one of the world\u2019s leading law firms representing investors in securities class action litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations, and the media as leading lawyers in the industry. Please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rgrdlaw.com&amp;esheet=52358928&amp;newsitemid=20210111005062&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.rgrdlaw.com&amp;index=2&amp;md5=dd003e213ee2eca1da05cba57970eabf\">http:\/\/www.rgrdlaw.com<\/a> for more information.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210111005062\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210111005062\/en\/<\/a><\/span><\/p>\n<p>\nRobbins Geller Rudman &amp; Dowd LLP<br \/>\n<br \/>J.C. Sanchez, 800-449-4900<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jsanchez@rgrdlaw.com\">jsanchez@rgrdlaw.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210111005062\/en\/221960\/3\/RGRD_FINAL.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Robbins Geller Rudman &amp; Dowd LLP announces that purchasers of Minerva Neurosciences, Inc. (NASDAQ:NERV) common stock between May 15, 2017 and November 30, 2020, inclusive (the \u201cClass Period\u201d), have until February 8, 2021 to seek appointment as lead plaintiff in the Minerva class action lawsuit, McCoy v. Minerva Neurosciences, Inc.,No. 20-cv-12176 (D. Mass.), which is assigned to Judge George A. O\u2019Toole, Jr. The Minerva class action lawsuit charges Minerva and its Chief Executive Officer with violations of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412110","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Robbins Geller Rudman &amp; Dowd LLP announces that purchasers of Minerva Neurosciences, Inc. (NASDAQ:NERV) common stock between May 15, 2017 and November 30, 2020, inclusive (the \u201cClass Period\u201d), have until February 8, 2021 to seek appointment as lead plaintiff in the Minerva class action lawsuit, McCoy v. Minerva Neurosciences, Inc.,No. 20-cv-12176 (D. Mass.), which is assigned to Judge George A. O\u2019Toole, Jr. The Minerva class action lawsuit charges Minerva and its Chief Executive Officer with violations of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased &hellip; Continue reading &quot;Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T14:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline\",\"datePublished\":\"2021-01-11T14:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/\"},\"wordCount\":1028,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/\",\"name\":\"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-11T14:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/","og_locale":"en_US","og_type":"article","og_title":"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline - Market Newsdesk","og_description":"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Robbins Geller Rudman &amp; Dowd LLP announces that purchasers of Minerva Neurosciences, Inc. (NASDAQ:NERV) common stock between May 15, 2017 and November 30, 2020, inclusive (the \u201cClass Period\u201d), have until February 8, 2021 to seek appointment as lead plaintiff in the Minerva class action lawsuit, McCoy v. Minerva Neurosciences, Inc.,No. 20-cv-12176 (D. Mass.), which is assigned to Judge George A. O\u2019Toole, Jr. The Minerva class action lawsuit charges Minerva and its Chief Executive Officer with violations of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased &hellip; Continue reading \"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T14:03:45+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline","datePublished":"2021-01-11T14:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/"},"wordCount":1028,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/","name":"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-11T14:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210111005062r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/robbins-geller-rudman-dowd-llp-updates-investors-in-the-minerva-neurosciences-inc-class-action-lawsuit-regarding-lead-plaintiff-motion-deadline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Robbins Geller Rudman &amp; Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412110"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412110\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}